Hansoh Pharmaceutical Group (SZSC:3692) - Stock Price, News & Analysis

3692 Stock Overview

An investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People’s Republic of China. More details

3692 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	1/6
Past Performance	5/6
Financial Health	5/6
Dividends	2/6

Rewards

Trading at 29.6% below our estimate of its fair value

Earnings are forecast to grow 2.54% per year

Earnings grew by 83.1% over the past year

Analysts in good agreement that stock price will rise by 22.7%

Risk Analysis

Significant insider selling over the past 3 months

Hansoh Pharmaceutical Group Company Limited Competitors

CSPC Pharmaceutical Group

SEHK:1093

HK$58.9b

Sino Biopharmaceutical

SEHK:1177

HK$59.9b

China Resources Pharmaceutical Group

SEHK:3320

HK$33.1b

China Medical System Holdings

SEHK:867

HK$18.8b

Price History & Performance

Summary of all time highs, changes and price drops for Hansoh Pharmaceutical Group
Historical stock prices
Current Share Price	HK$18.92
52 Week High	HK$22.80
52 Week Low	HK$11.18
Beta	0.65
11 Month Change	6.05%
3 Month Change	-3.47%
1 Year Change	22.22%
33 Year Change	14.39%
5 Year Change	-16.65%
Change since IPO	-24.02%

Recent updates

Shareholder Returns

	3692	HK Pharmaceuticals	HK Market
7D	1.8%	2.0%	1.4%
1Y	22.2%	-7.0%	14.9%

Return vs Industry: 3692 exceeded the Hong Kong Pharmaceuticals industry which returned -9.3% over the past year.

Return vs Market: 3692 exceeded the Hong Kong Market which returned 13.1% over the past year.

Price Volatility

Is 3692's price volatile compared to industry and market?
3692 volatility
3692 Average Weekly Movement	6.3%
Pharmaceuticals Industry Average Movement	6.7%
Market Average Movement	8.9%
10% most volatile stocks in HK Market	19.0%
10% least volatile stocks in HK Market	4.2%

Stable Share Price: 3692 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 3692's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1995	9,099	Huijuan Zhong	www.hspharm.com

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-tumor, anti-infection, central nervous system diseases, oncology, metabolic and autoimmune diseases, etc. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Hengmu, Mailingda, Hengsen, XINYUE, Saint Luolai, Fulaimei, Pulaitan, Tanneng, Ameining, Oulanning, Ruibote, Fulaidi, Fulairui, and Puruian tablets. The company serves pharmaceutical product distributors.

Hansoh Pharmaceutical Group Company Limited Fundamentals Summary

How do Hansoh Pharmaceutical Group's earnings and revenue compare to its market cap?
3692 fundamental statistics
Market cap	HK$112.28b
Earnings (TTM)	HK$5.04b
Revenue (TTM)	HK$12.94b

22.3x

P/E Ratio

8.7x

P/S Ratio

Is 3692 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
3692 income statement (TTM)
Revenue	CN¥12.10b
Cost of Revenue	CN¥1.09b
Gross Profit	CN¥11.01b
Other Expenses	CN¥6.30b
Earnings	CN¥4.71b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	0.79
Gross Margin	91.01%
Net Profit Margin	38.97%
Debt/Equity Ratio	0.1%

How did 3692 perform over the long term?

See historical performance and comparison

Dividends

2.0%

Current Dividend Yield

40%

Payout Ratio

3692 Stock Overview

Rewards

Risk Analysis

Hansoh Pharmaceutical Group Company Limited Competitors

SEHK:1093

HK$58.9b

SEHK:1177

HK$59.9b

SEHK:3320

HK$33.1b

SEHK:867

HK$18.8b

Price History & Performance

Recent News & Updates

Hansoh Pharmaceutical Group Company Limited Announces the Fifth New Drug Application of Ameile (Aumolertinib Mesilate Tablets) Was Accepted by the National Medical Products Administration

Hansoh Pharmaceutical Group Company Limited Announces the NMPA Has Granted Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate HS-20093

Hansoh Pharmaceutical Group Company Limited Announces Phase III Registrational Trial AENEAS2 Evaluating Ameile in Combination with Chemotherapy for Patients with Locally Advanced or Metastatic EGFR-Mutated NSCLC

First half 2024 earnings released: EPS: CN¥0.46 (vs CN¥0.22 in 1H 2023)

Upcoming dividend of HK$0.20 per share

First half dividend of HK$0.20 announced

Recent updates

Hansoh Pharmaceutical Group Company Limited Announces the Fifth New Drug Application of Ameile (Aumolertinib Mesilate Tablets) Was Accepted by the National Medical Products Administration

Hansoh Pharmaceutical Group Company Limited Announces the NMPA Has Granted Breakthrough-Therapy-Designated Drug for B7-H3-Targeted Antibody-Drug Conjugate HS-20093

Hansoh Pharmaceutical Group Company Limited Announces Phase III Registrational Trial AENEAS2 Evaluating Ameile in Combination with Chemotherapy for Patients with Locally Advanced or Metastatic EGFR-Mutated NSCLC

First half 2024 earnings released: EPS: CN¥0.46 (vs CN¥0.22 in 1H 2023)

Upcoming dividend of HK$0.20 per share

First half dividend of HK$0.20 announced

New major risk - Revenue and earnings growth

First half 2024 earnings released: EPS: CN¥0.46 (vs CN¥0.22 in 1H 2023)

Hansoh Pharmaceutical Group Company Limited Announces an Interim Dividend for the Six Months Ended June 30, 2024, Payable on 30 October 2024

Hansoh Pharmaceutical Group Company Limited to Report First Half, 2024 Results on Aug 27, 2024

Now 22% undervalued after recent price drop

Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ammeile for the Adjuvant Treatment of Egfr Mutation-Positive Non-Small Cell Lung Cancer Accepted by the National Medical Products Administration of the People's Republic of China

Now 22% undervalued

Upcoming dividend of HK$0.14 per share

Now 21% undervalued

Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.44 in FY 2022)

Hansoh Pharmaceutical Group Company Limited, Annual General Meeting, Jun 13, 2024

Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024

Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.44 in FY 2022)

Hansoh Pharmaceutical Group Company Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Now 24% undervalued after recent price drop

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of HS-10509 Tablets

Now 20% undervalued

Shanghai Hansoh Biomedical Technology Company Limited and Jiangsu Hansoh Pharmaceutical Group Company Limited Receives Clinical Trial Notice

Investor sentiment improves as stock rises 24%

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of Hs-20106 Injections

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-20105"

Upcoming dividend of HK$0.071 per share at 1.4% yield

Hansoh Pharmaceutical Group Company Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 28 September 2023

First half 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 1H 2022)

Hansoh Pharmaceutical Group Company Limited to Report Q2, 2023 Results on Aug 31, 2023

Investor sentiment deteriorates as stock falls 19%

Now 25% undervalued after recent price drop

Hansoh Pharmaceutical Group Company Limited Announces New Drug Application of Ibrexafungerp Tablets Accepted by the National Medical Products Administration

Hansoh Pharmaceutical Group Company Limited Announces HS-10518 Capsules A Category 1 Innovative Drug, Has Been Granted A Clinical Trial Notice

Hansoh Pharmaceutical Group Company Limited Provides Update on Clinical Trial Notice of HS-10516 Capsules

Hansoh (Shanghai) Healthtech Company Limited Obtains an Exclusive License from Biotheus Inc

Upcoming dividend of HK$0.05 per share at 0.7% yield

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10506 Tablets"

Full year 2022 earnings released: EPS: CN¥0.44 (vs CN¥0.46 in FY 2021)

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Approval of Oral Small Molecule 3CL Protease Inhibitor

Hansoh Pharmaceutical Group Company Limited Announces That " Hs-10390 Tablets " Has Been Granted A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of China

Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-10502 Tablets"

Hansoh Pharmaceutical Group Company Limited Announces European Medicines Agency Accepts Review of EQRx's Marketing Authorization Application for aumolertinib

Insufficient new directors

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.05 per share

Hansoh Pharmaceutical Group Company Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on 30 September 2022

First half 2022 earnings released: EPS: CN¥0.22 (vs CN¥0.22 in 1H 2021)

Hansoh Pharmaceutical Group Company Limited to Report First Half, 2022 Results on Aug 26, 2022

Investor sentiment improved over the past week

Upcoming dividend of HK$0.09 per share

Insufficient new directors

Hansoh Pharmaceutical Group Company Limited Proposes Final Ordinary Dividend for the Financial Year End December 31, 2021, Payable on July 15, 2022

Hansoh Pharmaceutical Group Company Limited Announces New Drug Application for the New Indication of Pegmolesatide Injections

Full year 2021 earnings released: EPS: CN¥0.46 (vs CN¥0.44 in FY 2020)

Full year 2021 earnings released: EPS: CN¥0.46 (vs CN¥0.44 in FY 2020)

Hansoh Pharmaceutical Group Company Limited Announces Final Dividend for the Year Ended December 31, 2021, payable on July 5, 2022